Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial

BACKGROUND: A raised blood eosinophil count (

• Christenson, S. A.
• Hanania, N. A.
• Bhatt, S. P.
• Bafadhel, M.
• Rabe, K. F.
• Vogelmeier, C. F.
• Papi, A.
• Singh, D.
• Laws, E.
• Dakin, P.
• Bansal, A.
• Lu, X.
• Bauer, D.
• Maloney, J.
• Robinson, L. B.
• Abdulai, R. M.